Published September 27, 2021 | Version v1
Report Open

Best-practice guidance for the health technology assessment of diagnostics and treatments for COVID-19

  • 1. 1. Science Policy and Research Programme, National Institute for Health and Care Excellence (NICE)
  • 2. 2. Medicines Analysis, NHS England and NHS Improvement, UK
  • 3. 3. National Health Care Institute (Zorginstituut Nederland), Netherlands
  • 4. 4. Syreon Institute, Hungary
  • 5. 3. National Health Care Institute (Zorginstituut Nederland), Netherlands,5. Utrecht Centre for Pharmaceutical Policy, Utrecht University, Netherlands
  • 1. Past Chair of HTAi Patient and Citizen Involvement Interest Group, UK
  • 2. NHS Healthcare Improvement Scotland, UK
  • 3. Institute for Clinical and Effectiveness Research (ICER), USA
  • 4. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), USA
  • 5. McGill University, Canada
  • 6. Erasmus University, Netherlands
  • 7. NHS Forth Valley, UK
  • 8. Gilead Sciences, UK
  • 9. NHS County Durham, UK
  • 10. British Thoracic Society, UK
  • 11. BioMereux, France
  • 12. MSD, UK
  • 13. Chair of the ISPOR Health Technology Assessment Council, Canada
  • 14. Ministry of Healthcare, Ukraine
  • 15. NHS England and NHS Improvement, UK
  • 16. Andalusian Health Technology Assessment Unit (AETSA), Spain
  • 17. International Alliance of Patients' Organizations, UK
  • 18. University of Sheffield, UK
  • 19. National Institute for Health and Care Excellence (NICE), UK


To support HTA agencies with consistent and pragmatic approaches, we have developed this best-practice guidance for the assessment of technologies for COVID-19. We focused on diagnostic and therapeutic technologies, as the most commonly assessed by HTA agencies. For therapeutics, we focused on treatments rather than post-exposure prophylaxis, however, the recommended approach is unlikely to be much different for prophylactic options.

The recommendations herein are based on findings from a survey and workshop of HTA agencies, a workshop with health economic modellers, and reviews of COVID-19 methods guidance, clinical guidelines, and economic evaluations. They have also been discussed with, and refined with input from, a multi-stakeholder group at a policy sandbox event. The recommendations span several themes relevant to HTA, and some of the key proposals are summarised below. Foremost among them is the recommendation that the pandemic is used as an opportunity to implement a responsive, “living” approach to HTA.


HTx-COVID-Guidance for HTA-Project report-V1.1_For publication.pdf

Files (1.2 MB)

Additional details


HTx – Next Generation Health Technology Assessment to support patient-centred, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe 825162
European Commission